Abstract: A treatment system that includes a treatment instrument to apply a treatment energy to a living tissue from an end effector according to a supplied electric power to incise the living tissue, an imaging device to generate a captured image capturing a state in which the treatment energy is applied from the end effector to the living tissue, and a control device that includes a processor to control operation of the imaging device. The processor acquires the captured image, calculates a temporal change amount based on any one of a predetermined point and a predetermined area in the captured image as a determination value, determines whether incision of the living tissue has been completed based on the determination value, and in response to determining that incision of the living tissue has been completed, execute an instruction to stop supply of the electric power to the treatment instrument.

Abstract: A treatment system includes a treatment tool, an imaging apparatus, and a control device. The treatment tool is configured to perform treatment on a living tissue by applying treatment energy from an end effector to the living tissue based on supplied electric power. The imaging apparatus captures an image of the living tissue in a state in which the treatment energy is applied from the end effector to the living tissue. The control device includes a processor to control the imaging apparatus by acquiring the captured image, determining whether an abnormality has occurred in the end effector based on the acquired captured image, and executing an instruction to stop supply of the electric power to the treatment tool when determining that the abnormality has occurred in the end effector.

Abstract: A processor of an electric power source device exercises control over a power output before a control switching time point based on a value related to initial impedance, and determines the control switching time point upon detecting that a value related to impedance of a living tissue is at a minimum. The processor sets a set electric-power value of the power output based on a parameter related to controlling the power output before the control switching time point, and performs constant-electric-power control by controlling the power output using the electric-power value at and after the control switching time point.

Abstract: A processor of an electric power source device exercises control over a power output before a control switching time point based on a value related to initial impedance, and determines the control switching time point upon detecting that a value related to impedance of a living tissue is at a minimum. The processor sets a set electric-power value of the power output based on a parameter related to controlling the power output before the control switching time point, and performs constant-electric-power control by controlling the power output using the electric-power value at and after the control switching time point.

Abstract: 1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ?CH— or ?N—, Y is —NH—, —NR4—, —S—, —O—, —CH?N—, —N?CH—, —N?N—, —CH?CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.

Abstract: 1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ?CH— or ?N—, Y is —NH—, —NR4—, —S—, —O—, —CH?N—, —N?CH—, —N?N—, —CH?CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.

Abstract: A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ?CH— or ?N—, Y is —NH—, —NR4—, —S—, —O—, —CH?N—, —N?CH—, —N?N—, —CH?CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.

Abstract: An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R3 (R3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R4 (R4 is a substituted or unsubstituted cycloalkyl group); R2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

Abstract: 1.

Abstract: An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): 1

Abstract: A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, 1

Abstract: An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R3 (R3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R4 (R4 is a substituted or unsubstituted cycloalkyl group); R2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

Abstract: An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): 1